Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular therapies in hepatocellular carcinoma: what can we target?

Literature DB >> 24573715

Molecular therapies in hepatocellular carcinoma: what can we target?

Roberto Galuppo¹, Dinesh Ramaiah, Oscar Moreno Ponte, Roberto Gedaly.

Abstract

Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2014 PMID： 24573715 PMCID： PMC4344119 DOI： 10.1007/s10620-014-3058-x

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

62 in total

Review 1. Current strategy for staging and treatment: the BCLC update and future prospects.

Authors: Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal: Semin Liver Dis Date: 2010-02-19 Impact factor: 6.115

2. New agents on the horizon in hepatocellular carcinoma.

Authors: Andrew X Zhu
Journal: Ther Adv Med Oncol Date: 2013-01 Impact factor: 8.168

Review 3. Cell signaling by receptor tyrosine kinases.

Authors: Mark A Lemmon; Joseph Schlessinger
Journal: Cell Date: 2010-06-25 Impact factor: 41.582

4. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors: Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal: N Engl J Med Date: 2003-04-24 Impact factor: 91.245

Review 5. Resection and liver transplantation for hepatocellular carcinoma.

Authors: Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal: Semin Liver Dis Date: 2005 Impact factor: 6.115

6. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

Authors: Michael Höpfner; Alexander Huether; Andreas P Sutter; Viola Baradari; Detlef Schuppan; Hans Scherübl
Journal: Biochem Pharmacol Date: 2006-03-10 Impact factor: 5.858

Review 7. Caught up in a Wnt storm: Wnt signaling in cancer.

Authors: Rachel H Giles; Johan H van Es; Hans Clevers
Journal: Biochim Biophys Acta Date: 2003-06-05

Review 8. Mechanisms of regulating the Raf kinase family.

Authors: Huira Chong; Haris G Vikis; Kun-Liang Guan
Journal: Cell Signal Date: 2003-05 Impact factor: 4.315

9. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

Authors: Francesco Caponigro
Journal: Anticancer Drugs Date: 2002-09 Impact factor: 2.248

Review 10. Farnesyl transferase inhibitors for patients with lung cancer.

Authors: Bruce E Johnson; John V Heymach
Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531

18 in total

1. MicroRNA-2053 overexpression inhibits the development and progression of hepatocellular carcinoma.

Authors: Tao Song; Ke Ma; Cui Zhao; Jijin Yang; Jingyu Liu
Journal: Oncol Lett Date: 2019-06-20 Impact factor: 2.967

Review 2. Cancer stem cells and evolving novel therapies: a paradigm shift.

Authors: Sangeetha Vasudevaraj Naveen; Kumar Kalaivani
Journal: Stem Cell Investig Date: 2018-01-23

3. miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway.

Authors: Hao Tang; Rong-Ping Li; Ping Liang; Ya-Long Zhou; Guang-Wei Wang
Journal: Oncol Lett Date: 2015-05-26 Impact factor: 2.967

Molecular therapies in hepatocellular carcinoma: what can we target?

Review 1. Current strategy for staging and treatment: the BCLC update and future prospects.

2. New agents on the horizon in hepatocellular carcinoma.

Review 3. Cell signaling by receptor tyrosine kinases.

4. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Review 5. Resection and liver transplantation for hepatocellular carcinoma.

6. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

Review 7. Caught up in a Wnt storm: Wnt signaling in cancer.

Review 8. Mechanisms of regulating the Raf kinase family.

9. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

Review 10. Farnesyl transferase inhibitors for patients with lung cancer.

1. MicroRNA-2053 overexpression inhibits the development and progression of hepatocellular carcinoma.

Review 2. Cancer stem cells and evolving novel therapies: a paradigm shift.

3. miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway.

Review 4. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis.

Review 5. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy.

Review 6. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.

Review 7. Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.

8. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.

9. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.

Review 10. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives.